BACKGROUND: Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. METHODS: We randomly assigned 365 adults with JAK2-positive polycythemia vera who we...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!